
Results
9
Stocks with a return on equity of over 30% and a debt to equity ratio below 1.
9 companies
Johnson & Johnson
Market Cap: US$486.5b
Engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide.
JNJ
US$201.62
7D
-1.8%
1Y
34.8%
Merck
Market Cap: US$247.5b
Operates as a healthcare company worldwide.
MRK
US$98.93
7D
-2.8%
1Y
-4.7%
Exelixis
Market Cap: US$11.9b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$42.17
7D
-2.9%
1Y
19.9%
ADMA Biologics
Market Cap: US$4.7b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$19.39
7D
0.05%
1Y
2.0%
CorMedix
Market Cap: US$832.0m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$11.26
7D
15.0%
1Y
20.4%
SIGA Technologies
Market Cap: US$444.0m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$6.15
7D
4.4%
1Y
-11.4%
Puma Biotechnology
Market Cap: US$272.1m
A biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
PBYI
US$5.40
7D
10.9%
1Y
78.8%
Abeona Therapeutics
Market Cap: US$263.9m
A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
ABEO
US$5.13
7D
7.3%
1Y
-13.3%
BioStem Technologies
Market Cap: US$66.3m
A life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services.
BSEM
US$4.33
7D
-5.0%
1Y
-75.4%